# Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

> **NCT01236040** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 521 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** GSK Biologicals' investigational vaccine GSK2590066A
- **BIOLOGICAL:** GSK Biologicals' investigational vaccine GSK2592984A
- **BIOLOGICAL:** GSK Biologicals' investigational vaccine GSK2340274A
- **BIOLOGICAL:** GSK Biologicals' investigational vaccine GSK2340273A
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01236040
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-29
- **Primary completion:** 2011-09-06
- **Final completion:** 2012-08-20
- **Target enrollment:** 521 (ACTUAL)
- **Last updated:** 2017-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01236040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01236040, "Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01236040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*